The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sychev D.A.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Shprakh V.V.

Irkutskiĭ gosudarstvennyĭ institut usovershenstvovaniia vracheĭ

Kitaeva E.Yu.

Irkutsk State Medical Academy of Postgraduate Education — Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education», Irkutsk, Russia

Mirzaev K.B.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Mickhalevich I.M.

Irkutsk State Medical Academy of Postgraduate Education — Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education», Irkutsk, Russia

Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke

Authors:

Sychev D.A., Shprakh V.V., Kitaeva E.Yu., Mirzaev K.B., Mickhalevich I.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(3‑2): 45‑52

DOI: 10.17116/jnevro201911903245

Read: 1149 times

Download PDF (RU)
Contact the author
Table of contents

GENETIC AND NON-GENETIC FACTORS OF LABORATORY RESISTANCE TO CLOPIDOGREL IN PATIENTS WITH ISCHEMIC STROKE
GENETIC AND NON-GENETIC FACTORS OF LABORATORY RESISTANCE TO CLOPIDOGREL IN PATIENTS WITH ISCHEMIC STROKE

To cite this article:

Sychev DA, Shprakh VV, Kitaeva EYu, Mirzaev KB, Mickhalevich IM. Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(3‑2):45‑52. (In Russ.)
https://doi.org/10.17116/jnevro201911903245

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Clinical and gene­tic asso­ciations in patients with non-cardioembolic ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):12-19
Biomarkers of athe­rothrombotic and cardioembolic subtypes of acute ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):20-26
Stage-by-stage treatment of a patient with severe combined trauma and heart rupture complicated by exte­nsive ischemic stroke. Piro­gov Russian Journal of Surgery. 2024;(10):121-129
Asso­ciation of inflammation and chro­nic fati­gue syndrome in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):79-87
Poly­morphic variants in the cluster of genes enco­ding trace amine rece­ptors and cognitive functioning in patients with schi­zophrenia spectrum diso­rders and healthy controls. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):122-128
Adva­nces in thro­mbectomy in the acute ischemic stroke. Russian Journal of Preventive Medi­cine. 2024;(10):137-143
Improving the effe­ctiveness of treatment of patients with post-stroke apha­sia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):22-28
Pharmacogenetic testing for personalized statin prescription in Moscow. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):49-55
The effe­ctiveness of drug therapy in the reha­bilitation of patients with post-stroke apha­sia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):132-139
Oxidative stress and antioxidant protection in diso­rders of cere­bral circulation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):114-119
Abstract:

To identify clinical and pharmacogenetic predictors of the efficacy of clopidogrel in patients with AI based on CYP2C19 and ABCB1 genotyping. Material and methods. Clinical and laboratory examinations were performed in 121 patients with AI, and CYP2C19 polymorphisms (CYP2C19*2 (G681A, rs4244285), CYP2C19*3 (G363A, rs4986893), CYP2C19*17 (C806T, rs12248560), ABCB1 (C3435T, rs1045642), associated with a disturbance of antiplatelet action of clopidogrel. The carriage of polymorphic markers of the studied genes was determined by the method of polymerase chain reaction in real time. Results and conclusion. In the group with laboratory resistance to clopidogrel, women prevailed (p<0.0001), atherothrombotic subtype was 80% (p=0.0384), the frequency of obesity ischemic stroke was 60% (p<0.0001). Univariate analysis of variance of CYP2C19 polymorphisms CYP2C19 (CYP2C19*2 (G681A, rs4244285), CYP2C19*3 (G363A, rs4986893), CYP2C19*17 (C806T, rs12248560), ABCB1 (C3435T, rs1045642) in patients with ischemic stroke, demonstrated a significant effect of CYP2C19 genotypes on the indicators of residual reactivity of platelets.

Keywords:

ischemic stroke
pharmacogenetics
CYP2C19 gene
ABCB1 gene
polymorphism
clopidogrel

Authors:

Sychev D.A.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Shprakh V.V.

Irkutskiĭ gosudarstvennyĭ institut usovershenstvovaniia vracheĭ

Kitaeva E.Yu.

Irkutsk State Medical Academy of Postgraduate Education — Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education», Irkutsk, Russia

Mirzaev K.B.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Mickhalevich I.M.

Irkutsk State Medical Academy of Postgraduate Education — Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education», Irkutsk, Russia

Close metadata

References:

  1. Gusev EI, Martynov MYu, Kamchatnov PR. Ischemic stroke. The current state of the problem. Doktor.Ru. 2013;5(83):7-12. Accessed October 8, 2018. (In Russ.) https://www.spn-rusmg.com/doctorru2013
  2. Stakhovskaya LV, Klochikhina OA, Bogatyreva MD, Kovalenko VV. Epidemiology of stroke in Russia according to the results of the territorial-population register (2009—2010). Zhurnal Nevrologii i Psikhiatrii im. C. C. Korsakova. 2013;113(5):4-10. (In Russ.) https://doi.org/10.14300/mnnc.2017.12046
  3. Stakhovskaya LV, Klochikhina OA, Bogatyreva MD, Chugunova SA. Analysis of the epidemiological indicators of recurrent strokes in the regions of the Russian Federation (based on the results of the territorial-population register 2009—2014). Consilium Medicum. 2016;09:8-11. Accessed October 8, 2018. (In Russ.) https://con-med.ru/magazines/consilium_medicum/consilium_medicum-09-2016/analiz_epidemiologicheskikh_pokazateley_povtornykh_insultov_v_regionakh_rossiyskoy_federatsii_po_ito/
  4. Cabral NL, Muller M, Franco SC, Longo A, Moro C, Nagel V, Liberato RB, Garcia AC, Venancio VG, Gonçalves AR. Three-year survival and recurrence after first-ever stroke: the Joinville stroke registry. BMC Neurology. 2015;15:70. https://doi.org/10.1186/s12883-015-0317-1
  5. Fauchier L, Clementy N, Pelade C, Collignon C, Nicolle E, Lip GY Patients With Ischemic Stroke and Incident Atrial Fibrillation: A Nationwide Cohort Study. Stroke. 2015;46(9):2432-2437. https://doi.org/10.1161/STROKEAHA.115.010270
  6. Arabidze GG, Kudentsova SN, Kudentsova EA. Therapeutic and deontological aspects of the rehabilitation of patients after ischemic stroke. Mediko-sotsial’naya Ekspertiza i Reabilitatsiya. 2014;2:6-10. (In Russ.)
  7. Parfenov VA, Verbitskaya SV. Prevention of recurrent non-cardioembolic ischemic stroke based on antiplatelet agents. Aterotromboz. 2016;2:89-97. (In Russ.)
  8. Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, Gurbel PA, Tantry U, Navarese EP, Siller-Matula JM. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Eur Heart J Cardiovasc Pharmacother Send to Eur Heart J Cardiovasc Pharmacother. 2017;1;3(4):221-234. https://doi.org/10.1093/ehjcvp/pvw044
  9. Spanos K, Kouvelos G, Matsagkas M, Giannoukas AD. Antiplatelet Resistance in Ischaemic Stroke Patients. Eur J Vasc Endovasc Surg. 2017;54:3-4. https://doi.org/10.1016/j.ejvs.2017.03.024
  10. Su Y, Cheng X, Dong Q. Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications. CNS Neurosci Ther. 2015;21(11):870-876. https://doi.org/10.1111/cns.12419
  11. Amarenco P, Sissani L, Labreuche J, Vicaut E, Bousser MG, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle H, Rothwell PM, Steg PG, Diener HC, Sacco RL, Greving JP, Algra A; PERFORM and PRoFESS Committees and Investigators. The Intracranial-B2LEED3S Score and the Risk of Intracranial Hemorrhage in Ischemic Stroke Patients Under Antiplatelet Treatment. Cerebrovasc Dis. 2017;43(3-4):145-151. https://doi.org/10.1159/000453459
  12. Zhao Y, Yang W, Tan Z, Wang W, Xiao W, Zeng J, Xu A. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology. 2017;2:e000072. https://doi.org/10.1136/svn-2017-000072
  13. Friz HP, Molteni M, Cimminiello C. The dogma of aspirin: a critical review of evidence on the best monotherapy after dual antiplatelet therapy. Thrombosis Journal. 2015;13:28. https://doi.org/10.1186/s12959-015-0059-8
  14. Gargiulo G, Windecker S, Vranckx P, Gibson CM, Mehran R, Valgimigli M. A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More? Circulation. 2016;134:1881-1906. https://doi.org/10.1161/CIRCULATIONAHA.116.023952
  15. Christiansen CB, Pallisgaard J, Gerds TA, Olesen JB, Jørgensen ME, Numé AK, Carlson N, Kristensen SL, Gislason G, Torp-Pedersen C. Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. BMC Neurology. 2015;15:225. https://doi.org/10.1186/s12883-015-0480-4
  16. Tornio A, Flynn R, Morant S, Velten E, Palmer C, MacDonald T, Doney A. Investigating Real‐World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records. Clin Pharmacol Ther. 2018;103(2):281-286. https://doi.org/10.1002/cpt.780
  17. Khalil BM, Shahin MH, Solayman MHM, Langaee T, Schaalan MF, Gong Y, Hammad LN., Al‐Mesallamy HO, Hamdy NM, El‐Hammady WA, Johnson JA. Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. Clin Transl Sci. 2016;9(1):23-28. https://doi.org/10.1111/cts.12383
  18. Shmidt EV. Classification of vascular lesions of the brain and spinal cord. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 1985;85(9):1281-1288. (In Russ.)
  19. Dong-mei Jia, Zhi-bin Chen, Mei-juan Zhang, Wen-jie Yang, Jia-li Jin, Yong-quan Xia, Chun-lei Zhang, Yuan Shao, Cong Chen, Yun Xu. CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China. Stroke. 2013;44:00-00. http://stroke.ahajournals.org/content/early/2013/05/02/STROKEAHA. 113.000823
  20. Wagner H, Angiolillo DJ, Ten Berg JM, Bergmeijer TO, Jakubowski JA, Small DS, Moser BA, Zhou C, Brown P, James S, Winters KJ, Erlinge D. Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. J Thromb Thrombolysis. 2014;38(2):127-136. https://doi.org/10.1007/s11239-013-0987-8
  21. Zhang YJ, Li MP, Tang J, Chen XP. Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives. Send to Int J Environ Res Public Health. 2017;14(3). https://doi.org/10.3390/ijerph14030301
  22. Gafarova ME, Domashenko MA, Korobkova DZ, Maksimova MYu, Loskutnikov MA, Shabalina AA, Kostyreva MV, Konovalov RN. Hemorheology and hemostasis in thrombolytic therapy of ischemic stroke. Annals of Neurology. 2015;9(1):4-11. (In Russ.). https://cyberleninka.ru/article/n/gemoreologiya-i-gemostaz-u-patsientov-s-ishemicheskim-insultom-pri-provedenii-tromboliticheskoy-terapii
  23. Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013;61:872-879. https://doi.org/10.1016/j.jacc.2012.11.040
  24. Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013;61:2495-2502. https://doi.org/10.1016/j.jacc.2013.02.058
  25. Morse BL, Kim RB. Is personalized medicine a dream or a reality? Crit Rev Clin Lab Sci. 2015;52(1):1-11. https://doi.org/10.3109/10408363.2014.950407
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.